Selected research
Market Structure
Global Acamprosate Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Acamprosate market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Acamprosate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Acamprosate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Acamprosate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Acamprosate is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Acamprosate include Teva, Merck Group, Mylan, Zydus Pharmaceuticals and Glenmark Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Acamprosate market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Acamprosate and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Acamprosate sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Acamprosate market size, projected growth trends, production technologies, key applications, and end-use industries.
Acamprosate Segment by Company
Teva
Merck Group
Mylan
Zydus Pharmaceuticals
Glenmark Pharmaceuticals
Acamprosate Segment by Type
333 mg Delayed Release Tablet
Others
Acamprosate Segment by Application
Hospital
Clinic
Others
Acamprosate Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acamprosate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Acamprosate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acamprosate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Acamprosate market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acamprosate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Acamprosate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Acamprosate in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 333 mg Delayed Release Tablet
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Teva
- Merck Group
- Mylan
- Zydus Pharmaceuticals
- Glenmark Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Acamprosate Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Acamprosate Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Acamprosate Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Acamprosate Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Acamprosate Market Dynamics
- 2.1 Acamprosate Industry Trends
- 2.2 Acamprosate Industry Drivers
- 2.3 Acamprosate Industry Opportunities and Challenges
- 2.4 Acamprosate Industry Restraints
3 Acamprosate Market by Manufacturers
- 3.1 Global Acamprosate Revenue by Manufacturers (2021-2026)
- 3.2 Global Acamprosate Sales by Manufacturers (2021-2026)
- 3.3 Global Acamprosate Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Acamprosate Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Acamprosate Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Acamprosate Manufacturers, Product Type & Application
- 3.7 Global Acamprosate Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Acamprosate Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Acamprosate Players Market Share by Revenue in 2025
- 3.8.3 2025 Acamprosate Tier 1, Tier 2, and Tier 3
4 Acamprosate Market by Type
- 4.1 Acamprosate Type Introduction
- 4.1.1 333 mg Delayed Release Tablet
- 4.1.2 Others
- 4.2 Global Acamprosate Sales by Type
- 4.2.1 Global Acamprosate Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Acamprosate Sales by Type (2021-2032)
- 4.2.3 Global Acamprosate Sales Market Share by Type (2021-2032)
- 4.3 Global Acamprosate Revenue by Type
- 4.3.1 Global Acamprosate Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Acamprosate Revenue by Type (2021-2032)
- 4.3.3 Global Acamprosate Revenue Market Share by Type (2021-2032)
5 Acamprosate Market by Application
- 5.1 Acamprosate Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Acamprosate Sales by Application
- 5.2.1 Global Acamprosate Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Acamprosate Sales by Application (2021-2032)
- 5.2.3 Global Acamprosate Sales Market Share by Application (2021-2032)
- 5.3 Global Acamprosate Revenue by Application
- 5.3.1 Global Acamprosate Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Acamprosate Revenue by Application (2021-2032)
- 5.3.3 Global Acamprosate Revenue Market Share by Application (2021-2032)
6 Global Acamprosate Sales by Region
- 6.1 Global Acamprosate Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Acamprosate Sales by Region (2021-2032)
- 6.2.1 Global Acamprosate Sales by Region (2021-2026)
- 6.2.2 Global Acamprosate Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Acamprosate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Acamprosate Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Acamprosate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Acamprosate Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Acamprosate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Acamprosate Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Acamprosate Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Acamprosate Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Acamprosate Revenue by Region
- 7.1 Global Acamprosate Revenue by Region
- 7.1.1 Global Acamprosate Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Acamprosate Revenue by Region (2021-2026)
- 7.1.3 Global Acamprosate Revenue by Region (2027-2032)
- 7.1.4 Global Acamprosate Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Acamprosate Revenue (2021-2032)
- 7.2.2 North America Acamprosate Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Acamprosate Revenue (2021-2032)
- 7.3.2 Europe Acamprosate Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Acamprosate Revenue (2021-2032)
- 7.4.2 Asia-Pacific Acamprosate Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Acamprosate Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Acamprosate Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Teva
- 8.1.1 Teva Company Information
- 8.1.2 Teva Business Overview
- 8.1.3 Teva Acamprosate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Teva Acamprosate Product Portfolio
- 8.1.5 Teva Recent Developments
- 8.2 Merck Group
- 8.2.1 Merck Group Company Information
- 8.2.2 Merck Group Business Overview
- 8.2.3 Merck Group Acamprosate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Merck Group Acamprosate Product Portfolio
- 8.2.5 Merck Group Recent Developments
- 8.3 Mylan
- 8.3.1 Mylan Company Information
- 8.3.2 Mylan Business Overview
- 8.3.3 Mylan Acamprosate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Mylan Acamprosate Product Portfolio
- 8.3.5 Mylan Recent Developments
- 8.4 Zydus Pharmaceuticals
- 8.4.1 Zydus Pharmaceuticals Company Information
- 8.4.2 Zydus Pharmaceuticals Business Overview
- 8.4.3 Zydus Pharmaceuticals Acamprosate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Zydus Pharmaceuticals Acamprosate Product Portfolio
- 8.4.5 Zydus Pharmaceuticals Recent Developments
- 8.5 Glenmark Pharmaceuticals
- 8.5.1 Glenmark Pharmaceuticals Company Information
- 8.5.2 Glenmark Pharmaceuticals Business Overview
- 8.5.3 Glenmark Pharmaceuticals Acamprosate Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Glenmark Pharmaceuticals Acamprosate Product Portfolio
- 8.5.5 Glenmark Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Acamprosate Value Chain Analysis
- 9.1.1 Acamprosate Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Acamprosate Production Mode & Process
- 9.2 Acamprosate Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Acamprosate Distributors
- 9.2.3 Acamprosate Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst